A meta-analysis of pemetrexed-based doublet compared with pemetrexed alone for the second-line treatment of advanced non-small-cell lung cancer

Bratislava Medical Journal

Volumn 115, Issue 4, 2014, Pages 233-237

  Sun, C T ^a   Xu, X ^b   Sheng, W ^a   Wang, X W ^a   Wen, S L ^b   Han, J Q ^a  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF SHANDONG FIRST MEDICAL UNIVERSITY   (China)

Author keywords

Docetaxel; Meta analysis; Non small cell lung cancer; Second line therapy

Indexed keywords

ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; GLUTAMIC ACID DERIVATIVE; GUANINE; PEMETREXED;

ARTICLE; COMPARATIVE STUDY; DISEASE COURSE; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; META ANALYSIS; MORTALITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84901987707     PISSN: 00069248     EISSN: 13360345     Source Type: Journal    
DOI: 10.4149/BLL_2014_048     Document Type: Article

References (20)

1. Hu Z, Chen X, Zhao Y, Tian T, Jin G et al. Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J Clin Oncol 2010; 28: 1721-1726.
2. Gao G, Chu H, Zhao L, Gui T, Xu Q et al. A meta-analysis of paclitaxel-based chemotherapies administered once every week compared with once every 3 weeks first-line treatment of advanced non-small-cell lung cancer. Lung Cancer 2012; 76: 380-386.
3. Novello S, Le Chevalier T. Chemotherapy for non-small-cell lung cancer. Part 1: Early-stage disease. Oncology (Williston Park) 2003; 17: 357-364.
4. Gridelli C, Rossi A, Morgillo F, Bareschino MA, Maione P et al. A randomized phase II study of pemetrexed or RAD001 as second-line treatment of advanced non-small-cell lung cancer in elderly patients: treatment rationale and protocol dynamics. Clin Lung Cancer 2007; 8: 568-571.
5. Noble J, Ellis PM, Mackay JA, Evans WK. Second-line or subsequent systemic therapy for recurrent or progressive non-small cell lung cancer: a systematic review and practice guideline. J Thorac Oncol 2006;1: 1042-1058.
6. Qi WX, Shen Z, Yao Y. Meta-analysis of docetaxel-based doublet versus docetaxel alone as second-line treatment for advanced non-small-cell lung cancer. Cancer Chemother Pharmacol 2012; 69: 99-106.
7. Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R et al. A prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinumbased chemotherapy. J Clin Oncol 2000; 18: 2095-2103.
8. Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non small cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 22: 1589-1597.
9. Barlési F, Jacot W, Astoul P, Pujol JL. Second-line treatment for advanced non-small cell lung cancer: a systematic review. Lung Cancer 2006; 51: 159-172.
10. Schuette W, Tesch H, Büttner H, Krause T, Soldatenkova V et al. Second-line treatment of stage III/IV non-small-cell lung cancer (NSCLC) with pemetrexed in routine clinical practice: evaluation of performance status and health-related quality of life. BMC Cancer 2012; 12: 14.
11. Smit EF, Burgers SA, Biesma B, Smit HJ, Eppinga P et al. Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer. J Clin Oncol 2009; 27: 2038-2045.
12. Schiller JH, von Pawel J, Schütt P, Ansari RH, Thomas M et al. Pemetrexed with or without matuzumab as second-line treatment for patients with stage IIIB/IV non-small cell lung cancer. J Thorac Oncol 2010;5: 1977-1985.
13. Moher D, Pham B, Jones A, Cook DJ, Jadad AR et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet 1998; 352: 609-613.
14. Chiappori A, Bepler G, Barlesi F, Soria JC, Reck M et al. Phase II, double-blinded, randomized study of enzastaurin plus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer. J Thorac Oncol 2010; 5: 369-375.
15. de Boer RH, Arrieta Ó, Yang CH, Gottfried M, Chan V et al. Vandetanib plus pemetrexed for the second-line treatment of advanced nonsmall-cell lung cancer: a randomized, double-blind phase III trial. Clin Oncol 2011; 29: 1067-1074.
16. Scagliotti GV, De Marinis F, Rinaldi M, Crinò L, Gridelli C et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small cell lung cancer. J Clin Oncol 2002; 20: 4285-4291.
17. Gatzemeier U, von Pawel J, Gottfried M, ten Velde GP, Mattson K et al. Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 2000; 18: 3390-3399.
18. de Marinis F, Pereira JR, Fossella F, Perry MC, Reck M et al. Lung Cancer Symptom Scale outcomes in relation to standard efficacy measures: an analysis of the phase III study of pemetrexed versus docetaxel in advanced non-small cell lung cancer. J Thorac Oncol 2008; 3: 30-36.
19. Tassinari D, Scarpi E, Sartori S, Tamburini E, Santelmo C et al. Second-line treatments in non-small cell lung cancer. A systematic review of literature and metaanalysis of randomized clinical trials. Chest 2009;135: 1596-1609.
20. Weiss GJ, Zeng C, Kelly K, Tran ZV, Bunn PA Jr. Single-institution experience with pemetrexed and bevacizumab as salvage therapy in advanced non-small-cell lung cancer. Clin Lung Cancer 2007; 8: 335-338.